The adult CNS like other tissues contains stem cells and

The adult CNS, like other tissues contains stem cells, and in some cases stem monocarboxylate transporters have been implicated in cancer, such as glioblastoma. Recently, membrane particles from cerebrospinal fluid have been used as a potential model for studying neurological disease (Huttner et al., 2008), and here we present an in vivo model to generate particles from hESCs. Here we demonstrate for the first time the phenomenon of MKLP+ particle aggregation in the lumen of neuroepithelial rosettes. This model system can be used to generate neural cells of various stages of differentiation and demonstrates the potential importance of polarity and junction type in the phenomenon of MKLP+ particle aggregation. This system can be used to study early neurulation events, such as the mechanism of MKLP+ particle release, a phenomenon not directly observed here, and apical membrane reduction in vitro, providing insight into one of the important cellular mechanisms of stem and progenitor cell maintenance. We conclude that early hESC derived neuro-epithelial rosettes can model early neurulation events, such as the transition from neural plate like cells to neural tube like cells (i.e. symmetric to asymmetric NE cell division) demonstrated by MKLP+ particle inheritance and distribution using junction type as an indication of stage. The following are the supplementary materials related to this article.
Acknowledgments
Introduction Human mesenchymal stromal cells (MSCs) represent an efficient treatment to augment tissue regeneration, ameliorate severe graft-versus-host disease post transplantation or modulate immune responses (Bernardo et al., 2009; Brooke et al., 2007; Salem and Thiemermann, 2010; Caimi et al., 2010). Clinical protocols were approved to use culture expanded MSCs which fulfilled the minimal consensus criteria ((Dominici et al., 2006) and www.clinicaltrials.gov). Preclinical treatment paradigms with genetically engineered MSCs as anti-tumor agents have achieved both tumor-specific targeting and a potential to affect metastatic disease therapeutically (Kidd et al., 2009; Spaeth et al., 2008). Based on the efficiency and biosafety studies conducted so far transgenic MSCs might embody a therapeutic option for individual patient treatment specifically if no other treatment was available. The MSCs can be readily transduced via adenoviral, retroviral or lentiviral vectors (Shakhbazau et al., 2008; Gnecchi and Melo, 2009). Marker transgene expression such as EGFP (enhanced green fluorescent protein), RFP (red fluorescence protein) or luciferase enabled to track the fate of MSCs within the organism (Olivo et al., 2008; Wang and Chen, 2008; Hung et al., 2010). Marker transgenes were also introduced in the form of a fusion gene as it was recently reported for EGFP fusion protein with IFNβ (Ling et al., 2010). Moreover, antitumor effect was achieved by MSCs expressing enzymes combined with respective prodrug and converted to cytotoxic metabolite(s): thymidine kinase (HSV-TK)+ganciclovir or cytosine deaminase (CD)+5-fluorocytosine (5FC) (Kumar et al., 2008; Klopp et al., 2011; Cavarretta et al., 2010; Kucerova et al., 2007; Matuskova et al., 2010; Kucerova et al., 2008). Most of the studies described therapeutic effect achieved in several types of tumors including experimental metastasis models. Engineered MSCs expressing transgenes with enzymatic function could be used for imaging properties as well. Hung et al. (2005) detected radiolabelled substrate retention indicative of HSV-TK-MSCs\' participation in tumor stroma via micro-PET imaging. Similarly, luciferase-expressing MSCs were used to determine the sites and the extent of MSCs\' engraftment in the context of inflammation, injury and tumor disease (Kidd et al., 2009). The impact of retroviral transduction process on the MSCs has to be carefully evaluated for any potential risk or unwanted changes in cellular properties. Viral vector does not seem to compromise the capability for multilineage differentiation of MSCs or the expression of surface markers regardless of the expressed transgenic protein (e.g. EGFP (Lee et al., 2001) or CDy::UPRT (Kucerova et al., 2007; Kucerova et al., 2008)). Kallifatidis et al. (2008) described earlier senescence of the transduced MSCs upon forced expression of EGFP or puromycin acetyltransferase. Therefore they suggest the use of engineered MSCs at low passages. Study of Piccoli et al. (Piccoli et al., 2008) showed that retroviral transduction and subsequent expression of dominant selection marker in stably transduced MSCs induced an increased production of reactive oxygen species although with no apparent biological consequence in MSCs. The MSCs with some other types of transgenes might potentially have increased risk of transformation induced by insertional mutagenesis and/or exogenous transgene interaction with the cellular signaling pathways (Momin et al., 2010). However, engineered MSCs expressing the prodrug-converting enzymes (such as HSV-TK or CD) have the “suicide” concept included within, which might make these MSCs safer for the therapeutic use. Nevertheless transgene with enzymatic function metabolizes intracellular substrates thus being capable to interfere with the cellular responses to various stimuli. Although we and the others have previously reported significant anti-tumor efficiency of transduced human mesenchymal stromal cells derived from human adipose tissue MSCs (AT-MSCs) in several xenotransplant models (Kumar et al., 2008; Fritz and Jorgensen, 2008; Vilalta et al., 2009), the effect of stable expression of exogenous protein on the MSCs\' properties has not been studied in much detail so far. Previously we have reported increased sensitivity of transduced CD-AT-MSCs to 5-fluorouracil (5FU) and also noticed an increased proliferation of transgenic CDy::UPRT-MSCs compared to the untransduced counterparts. In the present study we have analyzed whether these changes were mediated via inherent retrovirus sequences itself, transduction procedure or the expression of transgene CDy::UPRT with enzymatic function.